Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0 'Trigger' Trial of Niraparib in Newly-diagnosed Glioblastoma and Recurrent IDH1/2(+) ATRX Mutant Glioma

NCT05076513 is registered in ClinicalTrials.gov with Nader Sanai as lead sponsor.

NCT NCT05076513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05076513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0 'Trigger' Trial of Niraparib in Newly-diagnosed Glioblastoma and Recurrent IDH1/2(+) ATRX Mutant Glioma
Lead sponsor
Nader Sanai
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 29, 2021
Completion date
March 31, 2027
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gbm, glioblastoma, glioblastoma multiforme, glioblastoma multiforme of brain, glioma, glioma, malignant